AZRX - AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

AzurRx BioPharma (AZRX) announces that it has dosed the first patient in a phase 2 clinical trial of niclosamide for the treatment of COVID-19 gastrointestinal infections.FW-1022, which is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections, was administered to a volunteer in the Phase 2 RESERVOIR trial.Topline results from the trial are expected in the first quarter of 2022, the company said.The trial is designed as a two-part, two-arm, placebo-controlled mid-stage study, with the primary objectives of confirming the safety of FW-1022 in the treatment of patients with COVID-19-related GI infections and to evaluate its efficacy in clearing SARS-CoV-2 from the GI tract. Shares up nearly 1% premarket.

For further details see:

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study